CGCarolina Do Rosário Esteves Guimarães

Carolina Do Rosário Esteves Guimarães

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Carolina Do Rosário Esteves Guimarães has a total of 5 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Thiosemicarbazones and analogues as potential biofilm inhibitors of Candida albicans

    by Carolina Do Rosário Esteves Guimarães, Danilo Santana Galvão, Silvio Do Desterro Cunha, Humberto Fonseca de Freitas, Tânia Fraga Barros

    Biofilms are a virulence factor for Candida albicans, a common pathogen in human fungal infections, making them resistant to many commercial antifungals. Therefore, the discovery of compounds that inhibit and eradicate biofilms is a priority. As thiosemicarbazones have had their effect on Candida biofilms little explored, this study investigated the inhibitory and eradication activity of 30 thiosemicarbazones and analogues against C. albicans biofilms. After initial screening, four compounds were selected and compound 28 emerged as the most potent with BIC50 at 31.55 ± 1.18 µM. By scanning electron microscopy analysis, blastoconidia adhered to the reduced surface and reduced formation of pseudohyphae and hyphae was revealed. Despite the inhibitory activity, the four compounds failed to eradicate the biofilm by more than 50%. Thus, the results suggest that the compounds evaluated are very promising for the development of effective antibiofilm compounds and open up new perspectives for elucidating the mechanism of action.


  • Open Access

    Can use of probiotics drugs cause fungemia? – a literature review

    by Stefane dos Santos Carneiro, Humberto Fonseca de Freitas, Carolina Do Rosário Esteves Guimarães

    Commercially, there are many products sold as probiotics composed by Sacharomyces boulardii, with probiotic drugs being those that are widely used in different clinical situations. The probiotic efficacy of these agents is proven in many studies, as well as their safety in normal use situations. However, there have been some reports of fungemias related to the use of these probiotics in hospitals associated with some factors. Therefore, our objective is to review the knowledge about this association, focusing on the factors that provide it and the development mechanisms. For the development of fungemia associated with the use of probiotics, it is observed that it has greater development potential in patients using a central venous catheter. Although this is the main factor, others that reduce the patient's immune status, as well as reduce the intestinal defense barriers, contribute to this process, increasing the risk of fungemia. Despite the well-documented benefits of probiotics, their use must be carefully evaluated for each patient, due to factors that contribute to associate the use of probiotic drugs with the risk of developing bloodstream infection by S. boulardii. It is necessary, therefore, to include protocols that generate alerts about this risk and establish preventive measures.


  • Upregulation of secreted aspartyl proteinase genes of fluconazole-sensitive Candida albicans isolates

    by Carolina Do Rosário Esteves Guimarães, Humberto Fonseca de Freitas, Tânia Fraga Barros

    Candida albicans infection development depends on several factors associated with this etiological agent, including secreted aspartyl protease (Sap) production. Sap expression commonly occurs under selective pressure caused by the presence of antifungals. Fluconazole is the main antifungal drug used for treatment or prophylaxis. This study investigated the influence of inhibitory and sub-inhibitory fluconazole concentrations on Sap activity and their gene transcription for three clinical C. albicans isolates. Two isolates presented significant increases in Sap activity and transcription of SAP 1-8 genes in the presence of 1 MIC80 of fluconazole compared to the absence of the antifungal agent. The results suggest that the increase in Sap activity occurs due to an upregulation of the SAP gene transcription influenced by fluconazole. This suggests the importance of all SAP genes in the progression of bloodstream infections compared to primary tissue infection. However, this phenomenon does not occur everywhere, and it is multifactorial. This may be related to the selective pressure effect on transcription modulators. Although preliminary, these results open a new perspective for the study of virulence factors.